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Abstract
Background: New treatment options are needed to maintain and improve therapy for tuberculosis, which caused
the death of 1.5 million people in 2013 despite potential for an 86 % treatment success rate. A greater understanding
of Mycobacterium tuberculosis (M.tb) bacilli that persist through drug therapy will aid drug development programs.
Predictive biomarkers for treatment efficacy are also a research priority.
Methods and Results: Genome-wide transcriptional profiling was used to map the mRNA signatures of M.tb from the
sputa of 15 patients before and 3, 7 and 14 days after the start of standard regimen drug treatment. The mRNA profiles
of bacilli through the first 2 weeks of therapy reflected drug activity at 3 days with transcriptional signatures at days 7
and 14 consistent with reduced M.tb metabolic activity similar to the profile of pre-chemotherapy bacilli. These results
suggest that a pre-existing drug-tolerant M.tb population dominates sputum before and after early drug treatment,
and that the mRNA signature at day 3 marks the killing of a drug-sensitive sub-population of bacilli. Modelling patient
indices of disease severity with bacterial gene expression patterns demonstrated that both microbiological and clinical
parameters were reflected in the divergent M.tb responses and provided evidence that factors such as bacterial load
and disease pathology influence the host-pathogen interplay and the phenotypic state of bacilli. Transcriptional
signatures were also defined that predicted measures of early treatment success (rate of decline in bacterial load
over 3 days, TB test positivity at 2 months, and bacterial load at 2 months).
Conclusions: This study defines the transcriptional signature of M.tb bacilli that have been expectorated in
sputum after two weeks of drug therapy, characterizing the phenotypic state of bacilli that persist through
treatment. We demonstrate that variability in clinical manifestations of disease are detectable in bacterial sputa
signatures, and that the changing M.tb mRNA profiles 0–2 weeks into chemotherapy predict the efficacy of
treatment 6 weeks later. These observations advocate assaying dynamic bacterial phenotypes through drug
therapy as biomarkers for treatment success.
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Background
Tuberculosis (TB) caused the death of 1.5 million people
in 2013 despite potential for an 86 % treatment success
rate [1]. New drug regimens are needed to maintain and
improve therapy for tuberculosis, shortening treatment
duration and targeting drug-resistant bacilli which com-
plicate 3.5 % of new and 20.5 % of previously-treated TB
cases [1]. The standard chemotherapy regimen for drug-
sensitive TB uses combinations of 4 drugs over 6 months.
The recommended treatment for multidrug-resistant
TB lasts 18–24 months or more, with increasingly toxic
combinations of second-line drugs. Extended periods of
chemotherapy are required to remove sub-populations
of Mycobacterium tuberculosis (M.tb) bacilli that persist
through the early phase of antimicrobial drug treatment
[2]. A recent treatment shortening trial failed to show
non-inferiority despite evidence that the experimental
regimens were more bactericidal in the first 4 months
[3]. Evidence for the existence of persister populations
recalcitrant to treatment is accumulating; quantitation
of mycobacteria in serial sputum samples during treatment
with regimens containing isoniazid display a characteristic
biphasic pattern of killing, indicative of the presence of
multiple populations of M.tb [4]. The exposure of sputum-
derived bacilli to resuscitation-promoting factors unmasks
a previously-unculturable drug-tolerant population of M.tb
in sputum [5], and sub-populations of bacilli that only grow
in liquid culture and not on solid media may represent 90
% of bacilli in sputum [6]. Similar M.tb populations have
also been identified in chronic murine tuberculosis models
[7], and generated in vitro [8]. Microfluidic systems have re-
vealed heterogeneous mycobacterial responses to antibiotic
exposure in genetically-homogenous populations, providing
a basis for the generation of such sub-populations in vivo
[9]. It is unlikely that the duration of tuberculosis chemo-
therapy will be reduced until drug regimens are identified
that can kill these persister sub-populations.
Success in tuberculosis chemotherapy is measured by
the proportion of patients who fail therapy or who relapse
after treatment is completed; therapy is monitored by
counting M.tb in sputum and assaying markers of drug
toxicity. Clinical or microbiological parameters, such as
number of lung cavities or extent of lung cavitation, M.tb
culture positivity at 2 months [10] or bacterial load in
sputum before the start of treatment [11], are associated
with early treatment success but are poor predictors of
treatment outcome. For example, use of a combination of
biomarkers, culture negativity at 2 months and low extent
of cavitation by X-ray, failed to be predictive of individuals
where treatment could be shortened from 6 to 4 months
[12]. However, molecular profiling assays, such as those
used to identify tuberculosis disease from patient blood
transcriptional signatures [13, 14], have not been applied
to bacteria during patient drug therapy to assess the
predictive power of dynamic bacterial responses to anti-
microbial drug exposure.
The transcriptional signature ofM.tb reflects the bacterial
physiological state and offers insight into the mechanisms
required to survive [15–17]. An increased understanding of
which M.tb bacterial phenotypes survive chemotherapy
during natural infection will aid the design of novel inter-
vention strategies. To this end, M.tb bacilli have been pro-
filed from in vitro models that mimic hypothesized features
of M.tb persister populations [8, 18, 19]. Investigation
of the mRNA signature of M.tb derived from human
sputa revealed a slow/non-growing gene expression
pattern alongside an accumulation of lipid bodies, a ‘fat
and lazy’ phenotype [20]. In addition, by mapping the
differential expression of M.tb respiratory pathways, the
microenvironment surrounding bacilli was predicted to
be, at least in part, hypoxic [20]. This observation was
confirmed by 3-dimensional PET-CT imaging of human
lungs that highlighted the hypoxic and dynamic nature of
lesions within an individual [21]. Transcriptional profiling
the response of bacilli to drug exposure in vitro has helped
to define antimicrobial drug class of action and mecha-
nisms that may influence drug efficacy [22–24]. These
drug-inducible signatures, used as a bioprobe, may also
identify drug-tolerant M.tb populations by classifying di-
vergent responses to drug exposure [25, 26].
This study profiles sputumM.tb transcriptional responses
during the first 14 days of standard anti-tuberculous ther-
apy, testing the hypothesis that persister-type bacilli are the
dominant population in human sputum. Drug-induced
changes inM.tb gene expression were observed 3 days after
the start of chemotherapy that were not evident at 7 or 14
days. Furthermore, the profile of bacilli derived from spu-
tum one or two weeks after drug therapy resembled pre-
treatment sputum bacilli. This suggests that bacilli with a
phenotype able to survive drug therapy were already
present prior to the commencement of treatment. Bacteria
with a drug-responsive phenotype during days 0 to 3 were
no-longer present by day 7 and were presumably killed. Im-
portantly, we demonstrate for the first time that the diverse
pathology of human disease influences the phenotype of
M.tb bacilli in sputum. We show that microbiological
(bacterial load) and clinical (number of cavities) mea-
sures of disease were predicted from the changing M.tb
sputum signature over time, as were parameters with
prognostic value (positive TTP or MBL TB test, and
bacterial load at 2 months).
Methods
Patient sample collection, clinical and molecular
parameters
Subjects with active pulmonary tuberculosis (HIV nega-
tive, sputum smear-positive pulmonary TB) were recruited
in primary healthcare tuberculosis clinics in the Western
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Cape Province, South Africa following local ethical ap-
proval (Stellenbosch University Health Research Ethics
Committee, Study no 99/039). Patients consented to be in-
volved in the study. Details of the patients in this cohort
have been reported previously [11]. Clinical parameters
measuring severity of disease, such as average chest radio-
graph (CXR) score and number of observable cavities,
were recorded. Briefly, full-sized CXRs (postero-anterior
and lateral) were obtained and read by a pulmonologist
blinded to patient clinical history using a standardized
protocol [11]. Expectorated sputum was immediately col-
lected into 4 M GTC solution at the clinic as previously
described [27] and frozen at -80 °C. For each patient, sam-
ples were collected before the start of chemotherapy, and
3, 7 and 14 days after initiation of treatment. Standard 5
day/week clinic-based directly observed treatment (DOT)
was given by routine clinic nurses using fixed-dose
combinations, with dose adjustment based on patient
body weight. Treatment consisted of a 2-month inten-
sive phase of rifampicin, isoniazid, pyrazinamide, and
ethambutol, followed by a 4-month continuation phase
of rifampicin and isoniazid. Treatment was monitored
using microbiological (BACTEC 460) time-to-positivity
scores (TTP) at diagnosis (day 0), day 7 and day 14,
and by the molecular bacterial load (MBL) assay [27] at
diagnosis (day 0), day 3, 7, 14 and 56. Participants’ molecu-
lar, microbiological and clinical parameters are detailed in
Additional file 1: Table S1.
M.tb RNA extraction and amplification
Mycobacterial RNA was extracted from tuberculous
sputa as previously described using the GTC/Trizol
method [20]. Briefly, sputum was thawed and bacterial
pellets recovered from GTC by centrifugation at 1800 g
for 30 minutes. Bacterial pellets were resuspended in
Trizol (Life Technologies), disrupted using a ribolyzer
(MP Biomedicals) and the nucleic acid recovered in the
aqueous phase after addition of chloroform. The RNA
preparations were purified and DNase-treated using
RNeasy columns (Qiagen). Mycobacterial RNA yield and
quality were assayed using the Nano-Drop ND-1000
Spectrophotometer (NanoDrop Technologies) and Agilent
2100 Bioanalyser (Agilent Technologies). RNA samples
were amplified from 100 ng total RNA using the Messa-
geAmp II Bacteria system (Life Technologies) [16, 28]. All
sputum samples were extracted and amplified together to
minimize technical variation.
Transcriptional profiling M.tb from sputa
Amplified M.tb RNA derived from 15 subjects at mul-
tiple time intervals before and during chemotherapy
(totalling 52 samples) was profiled alongside M.tb
H37Rv RNA extracted from in vitro log phase bacilli
(two biological replicates hybridized in duplicate) as a
standardized comparator [16, 20]. Amplified mycobacter-
ial RNA (2 μg) was directly labelled with Cy3 fluorophore
using the Universal Linkage System (ULS, Kreatech
Diagnostics). Microarray hybridizations were conducted as
previously described [16, 20] using an M.tb complex pan-
genome microarray generated by the Bacterial Microarray
Group at St. George’s (ArrayExpress accession number A-
BUGS-41). Significantly differentially expressed genes were
identified using moderated t-tests (p-value <0.05 with Ben-
jamini and Hochberg multiple testing correction), and fold
change >2 (for aerobic comparisons) and >1.5 (for sputum
temporal responses) in GeneSpring 12.6 (Agilent Technolo-
gies). Samples were hierarchically clustered using Cluster
and Treeview [29]. Hypergeometric probability was used to
identify significantly enriched transcriptional signatures
from functional classifications or from published datasets.
Short time-series expression miner (STEM) was used to de-
termine significantly represented temporal gene expression
profiles (p <0.05 after Bonferroni multiple testing correc-
tion), identifying time-dependent transcriptional patterns in
bacilli extracted from human sputa [30]. Significant genes
identified in each comparison are detailed in Additional file
2: Table S2 and Additional file 3: Table S3.
Quantitative RT-PCR to verify transcriptional signatures
M.tb cDNA (20 μL) was prepared for each sample using
1 μg RNA per reaction (Maxima 1st strand cDNA syn-
thesis kit for RT-qPCR, Thermo Scientific) and amplified
according to the manufacturer’s instructions for high
GC templates. For pooled patient analyses, 10 μL first
strand synthesis products were combined for each time-
point. The two M.tb log phase samples were amplified in
triplicate and combined. Quantitative 5-plex PCR was
performed on a Rotor-Gene Q platform using Quanti-
Tect Multiplex PCR NoROX Kit (Qiagen). A total of 5
μL pooled cDNA was added per 25 μL reaction with 2×
QuantiTect reaction mix and 0.2 μM primer and probes
(Additional file 4: Table S4). Multiplex qPCR was run for
40 cycles according to the manufacturer’s instructions. In
each 5-plex set sigA was used to normalize input cDNA
concentration. Reactions were run in duplicate and ac-
cepted if replicate Cq values were within 1 cycle. Cq values
were used to determine changes in gene expression either
relative to day 0 (before treatment) or to log phase bacilli
using the 2-(delta delta Cq) method [31].
Modelling associations between RNA signatures and
microbiological/clinical parameters
Gene expression data were gathered into a matrix Xq ∈
ℝ52 × 4456 for quantile normalized and Xd ∈ ℝ37 × 4456 for
day 0 normalized data, with samples (patient, timepoint)
in rows and genes in columns. Both matrices were stan-
dardized so each column had a mean of 0 and standard
deviation of 1. Unsupervised dimensionality reduction
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technique principal component analysis (PCA) [32] was
applied to the gene expression matrix Xq to visualize
temporal movement of the samples in principal compo-
nent space. To investigate whether the gene expression
trajectories over the first two weeks of therapy followed
classifiable patterns, the patients (k) were divided into
two classes based on the variance of the PC data points
along the principal component axis: yk = − 1, if var(PC1) >
var(PC2) and yk = 1, otherwise. That is, the class corre-
sponds to the principal component axis along which the
PC data points of a patient has larger variance. These tar-
get classes were modelled using support vector machine
(SVM) [33] with gene expression data or clinical/micro-
biological variables as the predictors to define gene signa-
tures or clinical variables, after applying stability selection
or forward feature selection, respectively, that explained
the patient trajectories.
The relationships between theM.tb transcriptional profile
and patient clinical/microbiological variables were defined
using machine learning methods. Time-to-positivity was
modelled with Xq and other clinical variables with Xd.
Firstly, stability selection [34], implemented according to
the SCoRS framework, was used for feature selection [35].
A total of 500 sub-sampling iterations were performed with
a sub-sample that consisted of 500 features (columns in X)
and 2/3 of the samples (rows in X). Stability selection
yielded a set of stable, most predictive features of a particu-
lar clinical variable, which was used to train a regression or
classification model. To optimize the number of features
and to determine the predictive performance of the models,
nested leave-one-out cross-validation was carried out,
in which the inner loop determined the optimal num-
ber of variables and the outer loop the error of the
model (Additional file 5: Figure S1). The reported errors
are the average prediction errors of the test samples in the
outer loop. Continuous clinical variables time-to-positivity
and average chest X-ray score were modelled with L1-
norm regression (Lasso) [36], and the performance
evaluated with root mean squared error (RMSE) and
Pearson correlation coefficient between the fitted and
true values. Binary clinical variables, TB test positivity
at week 8 (MBL or TTP positive test vs. negative tests
at week 8), bacterial load at day 0 (MBL >= 106 bacilli
defined as high, MBL<106 classed as low), and rate of
decline in bacterial load from day 0 to 3 (ratio of MBL
at day 3 relative to day 0, MBL ratio >= 10 defined as
high, MBL ratio <10 classed as low) were modelled
with SVM. Molecular bacterial load at week 8 was
modelled with binary SVM by dividing the response
values into two bins based on the distribution of the
values (MBL week 8 <300 defined as low, MBL week 8
>=300 classed as high). Performance of the SVM
models was measured with average classification error, the
fraction of misclassified test samples in cross-validation.
All analyses, except the SCoRS algorithm, were imple-
mented with Matlab and R using their built-in functions.
Results
The transcriptional states of M.tb bacilli derived from
human sputa were mapped through the early stages of
chemotherapy. M.tb bacilli were isolated from the sputa
of 15 patients before chemotherapy was begun and then
at 3, 7 and 14 days of therapy with the standard regimen
(isoniazid, ethambutol, rifampicin and pyrazinamide). All
patients had non recurrent active tuberculosis and were
treated successfully for drug-sensitive tuberculosis and
all patients were culture negative at 3 months.
The ‘fat and lazy’ transcriptome of pre-chemotherapy
sputum-derived bacilli
The transcriptional profile of M.tb bacilli from sputa be-
fore the start of chemotherapy (day 0) was defined rela-
tive to bacilli grown in vitro in axenic log phase culture.
A total of 1083 genes were significantly differentially
expressed in sputum-derived bacilli (day 0) compared to
log phase growth, which revealed adaptations to respira-
tory and metabolic pathways (Fig. 1a/b, Additional file 2:
Table S2, Additional file 5: Figure S2 and Figure S3).
The sputum transcriptional signature was dominated by
the repression of genes involved in intermediate metab-
olism (II.A) and ribosome synthesis (II.A.1). These func-
tional categories (defined by Cole et al. [37]) were
significantly over-represented amongst down-regulated
genes (hypergeometric probabilities of 9.4x10-15 and
3.1x10-30, respectively). This drop in markers of cellular
activity was accompanied with the repression of central
metabolism and lipid biosynthesis, including the citric
acid cycle (gltA2, kgd, mdh, korA/B, sucC, rv0247c/48c,
fumC and mqo), FAS-1 (fas), FAS-II (fabD, acpM, kasA/
B, fabG1 and inhA), and mycolic acid synthesis and
modification (mmaA2/3/4, cmaA2, pcaA, fadD32 and
pks13) pathways [38, 39]. Conversely, genes involved in
the glyoxylate shunt pathway and methylcitrate cycle (icl,
prpC and rv1129c), catabolism of cholesterol and fatty
acids [40], and the predicted triacylglycerol synthases
(rv1425, rv1760, rv3087 and rv3371) [41] were induced in
sputum-derived bacilli. Thus, the M.tb sputum transcrip-
tome suggests that central carbon metabolism and general
metabolic activity is reduced in bacilli expectorated from
the lungs of tuberculosis patients, with an increased em-
phasis on lipolytic pathways. The transcriptomic evidence
also predicted that the respiratory state of bacilli was
altered in sputum with the down-regulation of NADH de-
hydrogenase I (nuoD/E/F/G/K), cytochrome C reductase
(qcrA/B/C) and aa3 cytochrome C reductase (ctaC/D/E)
pathways that are utilized in aerobic and microaerophilic
conditions [42]. Correspondingly, genes involved in nitrate
reduction (narK2/3) were induced, indicating the potential
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for a switch to alternative electron acceptors and anaer-
obic respiration. These adaptations are likely to be medi-
ated in part by the transcriptional regulator DosR (DevR)
that is induced by hypoxia and nitric oxide [43], with
several DosR-regulated genes significantly up-regulated
in sputa (nrdZ, narK2, rv1738, pfkB, hspX, hrp1,
rv3126c and rv3128c). Energy metabolism was also af-
fected as ATP synthase genes (atpA-G) were repressed
in sputum-derived bacilli; unsurprisingly the functional
categories for aerobic respiration (1.B.6.a) and ATP-
proton motive force (1.B.8) [37] were significantly
enriched in those genes down-regulated in sputum (hg
p-values 6.5x10-5 and 3.2x10-8, respectively). The differ-
ential expression of these pathways and gene families
are summarized in Fig. 1a and Additional file 5: Figure
S3. In addition, mRNA profiles of 10 metabolic and re-
spiratory indicator genes (icl, hspX, sigG, tgs1, prpC,
atpE, kasA, nuoA, qcrC and ctaD) were confirmed by
quantitative RT-PCR (Fig. 1b), the high concordance of
expression ratios between contrasting assays validating
our approach.
The M.tb mRNA signature 7 and 14 days into
chemotherapy resembles untreated bacilli
We were able to successfully extract, amplify and profile
mycobacterial RNA from sputa, after 3, 7 and 14 days
of standard chemotherapy despite falling bacterial vi-
able counts. Hierarchical clustering revealed that the
M.tb signatures from sputum-derived bacilli 14 days
after the start of drug therapy were most similar to
pre-chemotherapy (day 0) bacilli and day 7 bacilli, and
that profiles from day 3 clustered away from the other
time intervals (Fig. 2a, Additional file 5: Figure S4). These
observations from unsupervised hierarchical clustering
were supported by the results of pairwise significance test-
ing. A total of 109 genes were identified as significantly
differentially expressed at day 3 compared to day 0; in
comparison to 37 or 42 genes that were significantly
different between day 0 and days 7 or 14, respectively
(Fig. 2b/c, Additional file 3: Table S3). No genes were
significantly divergently expressed between day 7 and day
14 time intervals. The variation between sample profiles at
each time point were similar (Spearman’s rank correlations
Fig. 1 The transcriptional signature of M.tb bacilli in sputa relative to aerobic log phase growth before chemotherapy (D0) and 3 days (D3), 7
days (D7) and 14 days (D14) after beginning standard regimen drug therapy. a The 1337 genes significantly differentially expressed at any sputum
timepoint compared to axenic log phase bacilli are displayed as rows; each patient/timepoint as columns. Colouring details fold change relative to log
phase bacilli; red denoting up-regulation, blue repression. Adaptations to mycobacterial respiratory and metabolic state are summarized as text, listing
key indicator genes that were significantly regulated at D0. Grey columns (A-D) mark in which comparison each gene was identified. Clear boxes sign-
post clusters of genes that were differentially expressed over time. b Quantitative RT-PCR verification of 10 genes as key indicators of M.tb physiological
state measured in patient samples before treatment (day 0) and after 3, 7 and 14 days drug therapy. Genes induced in sputum icl, hspX, sigG, tgs1 and
prpC and genes repressed in sputum atpE, kasA, nuoA, qcrC and ctaD. Log2 expression ratios are plotted; the y-axis detailing fold change relative to log
phase bacilli. Error bars mark the standard error of the mean
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of 0.871 to 0.901, Fig. 2c), suggesting that the number of
statistically significant genes identified in each comparison
could be used reliably as a measure of similarity. A pattern
emerged, analogous to the unsupervised hierarchical clus-
tering, demonstrating thatM.tb responses at 7 and 14 days
during chemotherapy were most similar to that of bacilli
before drug therapy had begun.
The transcriptional signature from M.tb bacilli that
have persisted in patients through 14 days of standard
drug therapy was similar to the pre-chemotherapy profile;
for example, 501 of the 528 genes induced in sputum at
day 0 relative to log phase bacilli were also up-regulated in
sputum at day 14 (Fig. 1a, Additional file 2: Table S2).
Thus, the gross changes to metabolic and respiratory
pathways are comparable between sputum-derived bacilli
before and during chemotherapy. However, the magnitude
of transcriptional adaptations was elevated at day 14
compared to day 0; using aerobic log phase bacilli as a
comparator, 594 genes were significantly induced (605
genes repressed) at 14 days in contrast to 528 up-
regulated genes (555 down-regulated genes) at day 0
(Additional file 5: Figure S2, Additional file 2: Table S2). A
direct comparison of day 7 or day 14 transcriptional
profiles to day 0 revealed that M.tb gene expression
was predominately repressed with time (Fig. 2b/c); 37 genes
were significantly down-regulated at day 7 compared to day
Fig. 2 The M.tb mRNA signatures 7 and 14 days into chemotherapy resemble untreated bacilli. a Hierarchical clustering of M.tb transcriptional
profiles derived from sputa before the start of drug therapy (D0, black) and 3, 7 and 14 days into chemotherapy (D3, red; D7, blue; D14, purple).
The dendrogram is derived from clustering all genes (4456) and all sputum samples (52) after median centring. Individual patient study numbers
are marked. b M.tb genes significantly differentially expressed over time in sputa; at day 3 (top panel), day 7 (middle panel) and day 14 (bottom
panel) compared to pre-chemotherapy (day 0) bacilli. Log2 expression ratios are plotted 3, 7 and 14 days after the start of drug therapy; the y-axis
detailing fold change relative to day 0. Red colouring marks up-regulation, blue repression. c Table detailing M.tb responses to the early stages of
drug therapy. The number of genes significantly induced (red) or repressed (blue) in pairwise comparisons of sputum time points are marked in
the matrix. The mean Spearman’s rank correlation scores between samples at each time interval are also detailed (across the diagonal), demonstrating
that variation in replicate sputa at each time point did not bias the statistical testing
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0, and 37 genes were repressed at day 14 (29 overlapping
with day 7 signature), with five genes induced (Fig. 2b/c,
Additional file 3: Table S3). Of the genes that were down-
regulated over time, 88 % were also repressed in sputum
relative to log phase bacilli, suggesting that the non/slow-
growing phenotype of sputum-derived bacilli was further
enhanced over time and through chemotherapy. These
genes encode ribosomal proteins (rpmH and rpsJ), ribonu-
cleotide reductase subunits (nrdH and nrdI) involved in the
generation of precursors for DNA synthesis, and type VII
secretion system elements (esxA, esxB, esxH, esxN, esxO,
esxV, espD and espG3). In contrast, prpC, a methylcitrate
synthase up-regulated in day 0 bacilli relative to log phase
bacilli was down-regulated with drug therapy, indicating
that specific modifications to metabolic pathways may
occur over time.
Evidence of anti-mycobacterial drug action 3 days into
treatment
An inflection point at day 3 of chemotherapy was identi-
fied by mapping significantly represented temporal gene
expression profiles (Fig. 3a). Of the eight significantly
represented gene curves describing the M.tb response
to early drug therapy, six were modified at day 3 in
Fig. 3 The changing M.tb transcriptional pattern in sputum over time, highlighting day 3 as an inflection point. a Significantly represented
temporal gene expression profiles in M.tb bacilli extracted from sputa relative to log phase bacilli using short time-series expression miner (STEM).
The numbers of genes assigned to each gene expression curve are marked. b Quantitative RT-PCR defining day 3-specific induction of bkdC,
ndhA, nadA, kasB, iniB and efpA plotted at 3, 7 and 14 days after the start of drug therapy. Log2 expression ratios are plotted; the y-axis detailing
fold change relative to day 0 sputum bacilli. Error bars mark the standard error of the mean. c Significantly enriched gene clusters, previously
defined in response to antimicrobial drugs [23], in M.tb derived from sputum at 0, 3, 7 and 14 days after the start of chemotherapy. Greater
statistical significance is indicated by increasing depth of colour (minimum hypergeometric p-value <0.05). Gene clusters in red overlap with
genes up-regulated (blue, down-regulated) in sputum compared to aerobic log phase bacilli. Gene clusters are labelled numerically as in [23]. Ten
gene clusters were identified as significantly enriched only after drug treatment had started (marked with asterisks). Gene clusters 101, 31, 35 and
142 reflect exposure to pyrazinamide and rifampicin; cluster 45 to rifampicin alone; and cluster 87 to pyrazinamide alone. Of the ten enriched
drug responsive gene clusters, six were only significant at day 3
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comparison to day 0, 7 or 14 time intervals. The infer-
ence from this observation, that the mRNA signature 3
days after the start of chemotherapy was distinct from
the other sputa time points, was reinforced by hierarch-
ical clustering (Fig. 2a, Additional file 5: Figure S4) and
significance testing (Fig. 2b/c). A total of 83 genes were
significantly up-regulated 3 days after the start of drug
treatment compared to pre-chemotherapy bacilli. The
majority of these genes were also induced at day 3 relative
to both 7 and 14 days of drug therapy (Additional file 5:
Figure S5) suggesting that the day 3 transcriptional pattern
represented a short-lived response to the start of drug
treatment. This mRNA signature consisted of a diverse
subset of genes involved in intermediary metabolism (argF,
bkdC, galU, hisA, hisF, icl1, moaD1, pfkB, phoT and pstC1),
cell wall metabolism (alr, fbpD and murC) and response
to oxidative stress (alkB, cyp136 and rv0547c). The al-
ternative sigma factor sigG, induced as part of the
RecA-independent DNA damage response and impli-
cated in the regulation of detoxification systems [44],
was also up-regulated. Perhaps importantly, three genes
involved in the export of antimicrobial drugs were induced
at day 3: 1) rv1218c, encoding a putative ATP-dependent
efflux pump regulated by RaaS (rv1219c) that is function-
ally significant in the response to antimicrobial drugs in
non-permissive growth conditions [45]; 2) rv2688c, a
predicted ABC fluoroquinolone efflux pump [46]; and
3) rv3066, a mycobacterial transcriptional regulator of
the multidrug efflux pump Mmr (Rv3065) that has been
shown to influence mycobacterial resistance to multiple
toxic compounds [47]. Quantitative RT-PCR confirmed
the induction of bkdC, involved in branched amino acid
metabolism, ndhA, encoding a nonproton-pumping type
II NADH dehydrogenase, and nadA, a quinolinate synthe-
tase involved in NAD biosynthesis, at day 3 relative to day
0 (Fig. 3b). The maximal induction of sigG, hspX and tgs1
at day 3 was also verified by qRT-PCR (Fig. 1b).
To further explore the relationship between sputum
mRNA signatures and drug action in vivo, the transcrip-
tional adaptations to a range of antimicrobial drugs in vitro
[23] were mapped to the M.tb sputa profiles (Fig. 3c). Ten
gene clusters (responsive to drug exposure) were identified
to overlap with sputum transcriptional signatures exclu-
sively after drug treatment had started. Transcriptional pat-
terns reflecting exposure of bacilli to pyrazinamide and
rifampicin were observed providing molecular evidence of
in vivo drug action. Of the ten enriched drug responsive
gene clusters, six were only significant at day 3. Quantita-
tive RT-PCR of genes that are highly up-regulated after
M.tb exposure to cell-wall inhibitors [22, 23], exemplified
by iniB and efpA, were specifically induced at day 3 com-
pared to drug-free day 0 bacilli (Fig. 3b). The expression of
these benchmark genes for the activity of isoniazid and eth-
ambutol decreased at 7 and 14 days relative to day 3. Thus,
the transcriptional signature of bacilli 3 days into chemo-
therapy may reflect in vivo drug-induced changes; however,
many of these responses to drug action were short-lived
and were not evident 7 or 14 days after the start of drug
therapy. We hypothesize that these signatures represent the
killing of a drug-sensitive M.tb population after 3 days
chemotherapy, and reveal the presence of a pre-existing
drug-tolerant M.tb population that persists through early
drug treatment.
M.tb transcriptional signatures reflect patient disease and
predict treatment progress
All patients in this cohort were treated successfully for
tuberculosis: nine of 15 patients were culture negative at
2 months, and all patients were culture negative at 3
months. Microbiological time-to-positivity scores (TTP)
and molecular bacterial load (MBL) estimates were re-
corded alongside clinical parameters measuring severity
of disease (chest radiograph score and the number of
observable cavities) (Additional file 1: Table S1). Unsuper-
vised principal component analysis (PCA) plotting the first
and second principle components of the M.tb transcrip-
tional signatures from each patient over the first 2 weeks
of treatment time showed that M.tb responses followed
distinct trajectories (Fig. 4a). This suggested that M.tb re-
sponses to drug therapy may differ between patients and
that these bacterial mRNA signatures may reflect patient
disease severity or predict treatment progress. Interest-
ingly, two directions of travel emerged at 0–3 days with
South-North and East-West trajectories most common
(Fig. 4a and Additional file 5: Figure S6). Therefore, the
PC trajectories were grouped into two classes according to
the direction of movement in principal component space
(South-North or East-West). Unsurprisingly, since the
PCA patterns are a representation of the transcriptional
responses, support vector machine classification (SVM)
confirmed that PC trajectory class could be predicted from
the gene signatures (classification error of 8 %, linear ker-
nel). Furthermore, SVM was performed to test whether
clinical or microbiological parameters collected for each
patient would affect M.tb profiles such that the patient’s
membership in the South-North or East-West class could
be forecasted. The number of observed cavities in the lung
(at diagnosis) and the bacterial load at 8 weeks (MBL
measurement) predicted PC trajectory class with a classifi-
cation error of 13 %, a success rate of 87 %. These obser-
vations demonstrated that the expression profile of M.tb
in sputum was associated with specific measurable patient
parameters, that variability in clinical and microbiological
manifestations of disease could be detected in the bacterial
sputa signatures, which may also be of prognostic value.
These findings were expanded using L1-norm regres-
sion to model the impact of continuous clinical and
microbiological variables on M.tb sputa transcriptional
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profiles. Gene signatures were characterized that opti-
mally designated time-to-positivity (day 0, day 7, day 14)
with a RMSE (root mean squared error) of 3.6 hours.
The fitted compared to true data are plotted in Fig. 4b/c,
alongside the predictor gene set. The Pearson correlation
coefficient between true and predicted values was 0.59
with p-value 4.4x10-5. Transcriptional patterns were also
identified that correctly reflected patient chest X-ray
score (at day 0) with a RMSE of 13.9 CXR score, Pearson
correlation coefficient between true and predicted values
of 0.73 with p-value 3.7x10-7 (Fig. 4d/e). M.tb expression
profiles were also defined that were able to discriminate
between high (>=106 bacilli measured by MBL) and low
(<106 MBL bacilli) bacterial load at day 0 using a linear
SVM (with classification error of 5 %). Thus, these clin-
ical and microbiological parameters representing severity
of disease and number of bacteria correlated with meas-
urable changes in the M.tb transcriptional profile in
sputa over the first 14 days of drug therapy. Notably,
M.tb sputa signatures also predicted measures of early
treatment response. The rate of decline in bacterial load
from day 0 to day 3 (measured by MBL) was forecast
with a Gaussian SVM model with a classification error
of 3 %. TB test positivity at week 8 (positive wk 8 TTP
or MBL assay) was correctly classified using a Gaussian
SVM with a classification error of 11 % (successfully
calling treatment progress 89 % of the time). Similarly, a
high or low molecular bacterial load at week 8 could be
determined from the sputa transcriptional dataset using
SVM with a classification error of 0 %, 100 % test accur-
acy. Thus, the changing transcriptional profile of M.tb
derived from human sputa reflects features relevant to
Fig. 4 The associations between patient clinical and microbiological parameters and M.tb sputa transcriptional signatures. a M.tb responses to
drug therapy result in contrasting patient trajectories as defined by principle component analysis (PCA). The first (PC1) and second (PC2) principle
components of the M.tb transcriptional signatures from each patient at day 0, 3, 7 and 14 are plotted. Each point represents an M.tb mRNA profile
derived from a patient (coloured individually), arrows and dashed lines mark the direction and distance of movement of each patient from day 0 to day
14. Patient study identifiers are plotted at day 0. b/c Fitted (x-axis) against true (y-axis) time-to-positivity (TTP) values of test samples modelled using the
displayed set of 20 genes. y=x red line indicates ideal performance of the model; RMSE 3.6 hours, Pearson correlation coefficient 0.59, p-value
of 4.4×10-5. d/e Fitted (x-axis) against true (y-axis) chest x-ray scores of test samples modelled using the displayed set of 23 genes. y=x red line
indicates ideal performance of the model; RMSE 13.9 CXR score, Pearson correlation coefficient 0.73, p-value 3.7×10-7. RMSE root mean squared error,
CXR chest radiograph
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patient disease and may be used to predict early treat-
ment success.
Discussion
M. tuberculosis bacilli derived from human sputa 2
weeks after the start of treatment should be portrayed as
‘fat, lazy and indifferent’ to drug therapy. In this study
we were able to use genome-wide transcriptional profil-
ing to map the mRNA signatures of M.tb from the sputa
of clinically well-defined patients through the first 2
weeks of treatment, offering insight into the phenotypic
state of bacilli that persist through chemotherapy. This
contributes to our understanding of the in vivo efficacy
of combination drug regimens and may aid novel anti-
mycobacterial drug development programs targeting
drug-persistent bacilli. The pre-chemotherapy M.tb sig-
nature defined here extends and validates the findings of
a previous microarray study [20], confirming the M.tb
sputa profile in a larger cohort of clinically-defined pa-
tients collected independently in a different country and
assayed using a complementary profiling methodology.
In addition, single gene inferences were verified by qRT-
PCR using a panel of benchmark indicator genes.
The M.tb mRNA signatures 7 and 14 days after the
start of drug therapy were most similar to that of bacilli
before drug therapy had begun, as evidenced by hierarch-
ical clustering and differential gene expression analysis.
Transcriptional changes at 7 and 14 days also indicated
that the M.tb day 0 sputum phenotype was enhanced with
chemotherapy, with transcriptional markers of an active
metabolic state further repressed over time. This mirrors
findings from a recent study of M.tb in sputa using multi-
plex qRT-PCR that showed transition to a slow-growing
low-metabolic activity phenotype after the start of drug
treatment [48]. The broad changes in M.tb sputum physi-
ology reflected in these transcriptional patterns were con-
served between studies, where day 14 signatures were
more similar to day 7 than day 2 [48] or day 3 (this study).
However, we argue here that by using a well-defined log
phase M.tb population as a comparator (as applied in
many studies) enabled the pre-chemotherapy (day 0) M.tb
population to be characterized [20], allowing us to
propose that a pre-existing, slow/non-replicating and
likely drug-tolerant M.tb population dominates sputum
before, and after, early drug treatment. This conclusion is
supported by evidence from other studies identifying large
non-culturable on solid media or rpf-dependent M.tb sub-
populations in sputum prior to treatment [5, 6].
An inflection point in the mRNA profile 3 days after the
start of drug treatment, of stress-responsive genes includ-
ing mediators of drug efflux, likely represents the effects
of anti-TB drug action, using bacterial mRNA responses
as a bioprobe for cidal drug action during natural disease.
This transcriptional signature was only observed 3 days
into therapy and was absent after 7 or 14 days, where the
mRNA patterns were more similar to sputa bacilli before
treatment. We hypothesize that the mRNA signature at
day 3 marks the killing of a drug-sensitive sub-population
of bacilli, since these responses are not detected after
drug exposure in phenotypically drug-tolerant bacilli
[26]. By mapping previously-characterized in vitro M.tb
transcriptional responses to antimicrobial drugs, we were
able to define the in vivo action of standard regimen
chemotherapy in a clinical setting. The expression of
isoniazid-inducible benchmark genes (iniB, efpA) at day 3
alone suggest that the sputum bacterial population pro-
filed here 1 week after the start of chemotherapy no longer
respond to the antimicrobial actions of isoniazid. This
finding supports the Walter et al. study that detected an
isoniazid response in sputa bacilli 2 days after the start of
drug therapy that disappeared 7 days into treatment [48],
and mirrors evidence describing the bimodal early bacteri-
cidal activity of isoniazid in combination regimens [2, 4].
This study should be seen as capturing changes in M.tb
mRNA abundance rather than differential transcriptional
regulation since the structure of the underlying M.tb
population is unknown. Therefore, the transcriptional
read-out described here represents the average changes
in gene expression from shifting mycobacterial sub-
populations found in sputum. As such, lack of a response
to drug therapy might reflect limited exposure of bacilli to
antimicrobial drugs [49] and/or the presence of drug-
tolerant bacterial populations that are able to survive drug
treatment. The development of mycobacterial phenotypic
drug tolerance has been described in many in vitro models
for tuberculosis [8, 18, 19] and is often associated with a
slow/non-replicating bacterial state, such as that inferred
from the sputum M.tb mRNA signature. Moreover, re-
cent observations using single cell reporter technology
described the development of non-growing but
metabolically-active mycobacterial sub-populations during
murine infection [50]. Our study further emphasizes the
significance of drug-tolerant bacilli in human tubercu-
losis, identifying a transcriptionally-activeM.tb population
that persists through 2 weeks of standard chemotherapy.
Modelling M.tb gene expression in the sputa of patients
over time revealed that the transcriptional pattern of ba-
cilli varied from patient to patient with drug treatment.
Correlation of patient indices of disease severity with bac-
terial mRNA signatures showed that basic microbiological
(time-to-positivity, bacterial load at day 0) and clinical
(chest radiograph score) parameters were reflected in the
divergent M.tb responses. These associations suggest that
factors such as bacterial load and disease pathology influ-
ence the host-pathogen interplay and, thus, the phenotypic
state of bacilli, which in turn might affect the natural his-
tory of patient disease. Importantly, this demonstrates for
the first time that the diverse pathology of tuberculosis
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affects measurable changes on the phenotype of M.tb ba-
cilli in sputa. Notably, transcriptional signatures were also
identified that predicted measures of early treatment suc-
cess (rate of decline in bacterial load over 3 days, MBL or
TTP positivity at 2 months, bacterial load at 2 months).
Although this study was not significantly powered to test
these signatures, these observations highlight the potential
use of assaying dynamic bacterial phenotypes through
drug therapy as biomarkers for treatment efficacy. These
data are supported by recent evidence suggesting that
higher percentages of lipid-body-positive acid-fast bacilli
3–4 weeks after the start of treatment, rather than initial
baseline counts, correlated with treatment failure or re-
lapse [51]. We demonstrate here a novel concept and
proof-of-principle that proposes using the changing tran-
scriptional state of infecting bacilli to monitor treatment
success.
Conclusions
This study defines the transcriptional signature of bacilli
in sputum after 2 weeks of drug treatment, mapping the
molecular phenotype of persister-type bacilli. We dem-
onstrate for the first time that variability in clinical man-
ifestations of disease are detectable in bacterial sputa
signatures, and that the changing M.tb mRNA profiles
0–2 weeks into chemotherapy predict the efficacy of
treatment 6 weeks later. These findings advocate a novel
biomarker discovery strategy, profiling the phenotype of
infecting bacteria, to find predictive markers of treatment
success that are desperately needed in clinical trials and to
stratify at-risk patients in the clinic.
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